Get the Stockscreener App
2.09
0.00%
0.00
After Hours:
2.09
Mural Oncology Plc stock is traded at $2.09, with a volume of 55,884.
It is up +0.00% in the last 24 hours and up +0.48% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.09
Open:
$2.08
24h Volume:
55,884
Relative Volume:
0.20
Market Cap:
$36.21M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.48%
1M Performance:
+0.48%
6M Performance:
-20.83%
1Y Performance:
-39.60%
1-Day Range:
$2.08
$2.09
1-Week Range:
$2.08
$2.10
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.09 | 36.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
BlackRock discloses 1.64% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.11% stake in Mural Oncology - Investing.com
BlackRock discloses 1.64% stake in Mural Oncology By Investing.com - Investing.com UK
How Mural Oncology plc stock performs during Fed tightening cyclesEarnings Performance Report & Growth Focused Stock Reports - newser.com
Combining price and volume data for Mural Oncology plcJuly 2025 Market Mood & Real-Time Buy Signal Notifications - newser.com
Is Mural Oncology plc a candidate for recovery play2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
Is Mural Oncology plc stock ready for a breakoutJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - newser.com
Mural Oncology shareholders approve acquisition by XRA 5 Corp. - MSN
What candlestick patterns are forming on Mural Oncology plc2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Exit strategy if you’re trapped in Mural Oncology plcJuly 2025 Summary & Weekly Stock Performance Updates - newser.com
Is Mural Oncology plc stock attractive for growth ETFsDollar Strength & Free Real-Time Market Sentiment Alerts - newser.com
REGCitadel Group Mural Oncology PLCForm 8.3Mural Oncology plc - TradingView
Will Mural Oncology plc stock maintain dividend yieldMarket Risk Report & Smart Allocation Stock Tips - newser.com
Can trapped investors hope for a rebound in Mural Oncology plc2025 Historical Comparison & Fast Gain Stock Trading Tips - newser.com
Published on: 2025-10-31 04:17:55 - newser.com
Why Mural Oncology plc stock is favored by pension funds2025 Trading Recap & Verified Swing Trading Watchlists - newser.com
Mural Oncology plc (MURA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Mural Oncology plc (MURA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Form 8.3The Vanguard Group, Inc.: Mural Oncology plc - TradingView
Why AXIL stock could see breakout soonTrade Risk Summary & Weekly Top Gainers Trade List - newser.com
Chart overlay techniques for tracking Mural Oncology plcTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com
Citadel Group discloses 1.08% stake in Mural Oncology By Investing.com - Investing.com Australia
Can Mural Oncology plc stock resist sector downturnsMarket Weekly Review & Risk Controlled Swing Alerts - fcp.pa.gov.br
Citadel Group discloses 1.08% stake in Mural Oncology - Investing.com
Citadel Group discloses 0.99% stake in Mural Oncology By Investing.com - Investing.com Australia
Will Mural Oncology plc stock benefit from commodity pricesQuarterly Trade Report & Short-Term High Return Ideas - fcp.pa.gov.br
Why Mural Oncology plc stock could rally in 2025Analyst Upgrade & Accurate Entry/Exit Alerts - Fundação Cultural do Pará
Will Mural Oncology plc stock attract more institutional investorsPrice Action & Capital Efficiency Focused Ideas - fcp.pa.gov.br
Mural Oncology Plc Announces Acquisition by XOMA Royalty Corporation - MSN
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):